Angiosarcomas are rare, heterogeneous and a retrospective study was conducted to describe their natural history. We reviewed 161 files of angiosarcoma treated in three institutions of the French Sarcoma Group from 1980 to 2004. Survival and prognostic factors for survival were analyzed. Median age was 52 years. Primary sites were the breast (35%), skin (20%) and soft tissues (13%). At initial diagnosis, 31 (19%) had metastases. Surgery was the first treatment in 121 (75%) patients combined with chemotherapy or radiotherapy in 34 and 32, respectively. Ninety (74%) of these 121 patients relapsed, mostly locally (50). With an average time since initial diagnosis of 8.1 years, 123 (76%) patients progressed and 76 (47%) died. Median survival was 3.4 years 95% confidence interval (CI) 2.4–5.8, and the 5-year overall survival (OS) rate was 43% (95% CI 33–53). In multivariate analysis, liver primary site relative risk (RR) = 12.62, performance status (PS) of two or more (RR = 3.83), presence of metastases at diagnosis (RR = 2.50), soft tissue tumor (RR = 0.31) were correlated to OS. PS, liver and soft tissue tumors were identified as independent prognostic factors for progression-free survival. Angiosarcomas have an overall poor outcome, but with a clearly distinct prognosis depending on the primary site.